Ambulatory Blood Pressure Monitoring

William White

Looking at Lecanemab’s Eligibility Guidelines and Prescription Proce…

Dementia Matters Podcast

N. Chin

Lp(a): When to Measure it and What to Do About it

Collaborative CME and Research Network

M. O'Donoghue

Should Colchicine Become Standard Therapy for CAD?

Collaborative CME and Research Network

P. Ridker

CT Coronary Calcium Scoring, Hard Plaque and Soft Plaque Visualizati…

Scripps Health

M. Budoff

Differentiating Early Signs of Alzheimer Disease From Normal Signs o…

ACHL

J. Galvin

Updated Lipid Guidelines and Therapy

Complex Coronary Cases

I. Fergus

Role of Coronary Calcification and Risk Stratification

The Texas Heart Institute

E. Hernandez

Recent Cholesterol Guidelines and Integration into Clinical Practice

Vasculearn Network

J. Plutzky, L. Braun, J. Ross

Aducanumab FDA Approval for Alzheimer's Disease: The Importance of G…

Anton Porsteinsson

Do Triglycerides Cause Heart Disease?

National Lipid Association

I. Goldberg

AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 4…

AHA 2022 Conference Coverage

N. Marston

Cardiology’s Biggest Controversy: The Lumen or the Wall - the Curiou…

Cedars Sinai

J. Forrester

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

AHA 2022 Conference Coverage

K. Ray

Directions of Cardiology in the Next Decade: 2022-2032

Houston Methodist DeBakey Heart and Vascular Center

E. Braunwald

Coronary Calcium Testing: Principles and Clinical Application

Right Care Initiative

A. Taylor

The Deadly Paradox: Current Practice, Driven by Guidelines, Is Not A…

Michael Makover

How Do I Reverse Coronary Plaque?

Scripps Health

C. J. Suhar

Colchicine: Now and What’s Next?

National Lipid Association

C. Ballantyne

Evaluate the Horrible Cholesterol Lp(a): Prevalence, Impact and Nove…

Scripps Health

N. Lepor